ro 8-0576 has been researched along with levodopa in 200 studies
| Studies (ro 8-0576) | Trials (ro 8-0576) | Recent Studies (post-2010) (ro 8-0576) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 214 | 63 | 67 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | ro 8-0576 (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 65 (32.50) | 18.7374 |
| 1990's | 36 (18.00) | 18.2507 |
| 2000's | 23 (11.50) | 29.6817 |
| 2010's | 67 (33.50) | 24.3611 |
| 2020's | 9 (4.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gerlach, J | 1 |
| Barsegian, GG; Butenko, OB; Kordzadze, RN | 1 |
| Coper, H; Hausmanowa-Petrusewicz, I; Kaminska, A; Ossowska, K; Schulze, G; Wolfarth, S | 1 |
| Kleedorfer, B; Poewe, W | 1 |
| Chen, S | 1 |
| Jenkins, JR; Pearce, JM | 1 |
| Da Prada, M | 1 |
| Graham, JS; Henderson, JM; Morris, JG; Yiannikas, C | 1 |
| Cunningham, MA; Darby, DG; Donnan, GA | 1 |
| Agnoli, A; Carta, A; Marsden, CD; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F | 1 |
| Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A | 1 |
| Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H | 1 |
| Blackburn, NA; Boddie, HG; Ellis, CJ; Kendal, BR; MacMahon, DG; Sachdev, D | 1 |
| Lees, AJ | 2 |
| Jansen, EN; Meerwaldtt, JD | 1 |
| Covicković-Sternić, N; Kostić, VS | 1 |
| Bruggi, P; Martignoni, E; Nappi, G; Pacchetti, C; Sibilla, L; Turla, M | 1 |
| Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC | 1 |
| Allievi, C; Bellotti, V; Benedetti, MS; Dordain, G; Dostert, P | 1 |
| Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V | 1 |
| Rammsayer, T | 1 |
| Rinne, JO; Rinne, UK | 1 |
| Dordain, G; Dostert, P; Strolin Benedetti, M; Vernay, D | 1 |
| Campanella, G; De Michele, G; Filla, A; Mengano, A; Trombetta, L | 1 |
| Ingvarsson, PE; Johnels, B; Steg, G; Thorselius, M; Valls, M | 1 |
| d'Anglejan Chatillon, J | 1 |
| Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Allain, H; Bentue-Ferrer, D; Defawe, G; Jacquemard, F; Milon, D; Moran, P | 1 |
| Boomsma, F; Hovestadt, A; Man in't Veld, AJ; Meerwaldt, JD; Schalekamp, MA | 1 |
| Liu, DK | 2 |
| Caraceni, T; Lamperti, E; Lorizio, A; Nordera, N | 1 |
| Koller, WC; Lang, AE; Marsden, CD; Quinn, NP | 1 |
| Albani, C; Hacisalihzade, SS; Mansour, M | 1 |
| Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A | 1 |
| Cossutta, E; Ferrante, C; Pezzoli, G; Scarlato, G; Tesei, S; Zecchinelli, A | 1 |
| Ketsche, R; Vogel, HP | 1 |
| Stern, G | 1 |
| Mondal, BK; Mondal, KN | 1 |
| Birkmayer, GD; Birkmayer, W | 1 |
| Csanda, E; Takáts, A; Tárczy, M | 1 |
| Birkmayer, W | 1 |
| Da Prada, M; Haefely, WE; Kettler, R; Schaffner, R; Zürcher, G | 1 |
| Battegay, R; Gastpar, M; Zmilacher, K | 1 |
| Marion, MH; Marsden, CD; Quinn, NP | 1 |
| Aymard, N; Holzer, J; Rondot, P; Ziegler, M | 2 |
| Erni, W; Held, K | 1 |
| Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 1 |
| Ludin, HP | 2 |
| D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP | 1 |
| Baas, H; Fischer, PA | 1 |
| Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J | 1 |
| Lees, AJ; Poewe, WH; Stern, GM | 1 |
| Jansen, EN; Meerwaldt, JD | 1 |
| Wermuth, L | 1 |
| Bondarenko, NA; Kudrin, VS; Miroshnichenko, II | 1 |
| Rinne, UK | 1 |
| Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP | 1 |
| Crevoisier, C; Da Prada, M; Hoevels, B; Zürcher, G | 1 |
| Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A | 1 |
| Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO | 1 |
| Siegfried, J | 1 |
| Jenner, P; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F | 1 |
| Wilson, JA | 1 |
| Albani, C; Asper, R; Baumgartner, G; Hacisalihzade, SS | 1 |
| Birkmayer, W; Hars, V; Knoll, J; Marton, J; Riederer, P; Youdim, MB | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Steinhäusl, H | 1 |
| Casey, DE; Gerlach, J | 1 |
| van der Zee, HJ; van Nieuwenhuizen, O; Zweije-Hofman, IL | 1 |
| Iadgarov, IS; Kandel', EI | 1 |
| Csanda, E; Katona, G; Köves, A; Mogyorós, I; Takáts, A; Tárczy, M | 1 |
| Csanda, E; Tárczy, M | 1 |
| Kamenetskiĭ, VK | 1 |
| Caraceni, T; Cocchi, D; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A | 1 |
| Klingler, M | 1 |
| Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S | 1 |
| Caraceni, T; Giovannini, P; Martinez-Campos, A; Müller, EE; Novelli, A; Parati, E | 1 |
| Dessibourg, CA; Gachoud, JP | 1 |
| Dovedova, EL; Gershteĭn, LM | 1 |
| Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N | 1 |
| Gershteĭn, LM; Kukuev, LA; Sergutina, AV | 1 |
| Himori, N; Mishima, K | 1 |
| Baas, H; Bergemann, N; Fischer, PA | 1 |
| Akaike, N; Himori, N; Kurasawa, M; Mishima, K; Tanaka, Y | 1 |
| Bowes, SG; Charlett, A; Dobbs, RJ; Dobbs, SM; Nicholson, PW; O'Neill, CJ; Purkiss, A; Weller, C | 1 |
| Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C | 1 |
| Dubuis, R; Limousin, P; Perret, JE; Pfefen, JP; Pollak, P; Tournier-Gervason, CL | 1 |
| Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J | 1 |
| Shan, DE; Yeh, SI | 1 |
| Cammarota, A; Leiguarda, R; Merello, M; Pikielny, R | 1 |
| Gao, L; Han, W; Pu, L; Shao, C; Sun, Y; Yang, H; Zhang, Y | 1 |
| Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F | 1 |
| Leiva, C | 1 |
| Goetz, CG | 1 |
| Prevett, MC; Rossor, MN | 1 |
| Bennett, KM; Bonfiglioli, C; Castiello, U; Peppard, RF | 1 |
| Barbarino-Monnier, P; Denis, E; Lurel, S; Routiot, T | 1 |
| Golubev, VL; Sadekov, RA; Vendrova, MI | 1 |
| Brüne, M; Gerlach, G; Schröder, SG | 1 |
| Bartholomé, B; Bartholomé, K; Blau, N; Bonafé, L; Skrygan, M | 1 |
| Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T | 1 |
| Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M | 1 |
| Gu, SD; Sun, XF; Wang, W; Zhao, DZ | 1 |
| Li, Y; Tang, X | 1 |
| Ianishevskiĭ, SN; Kovalenko, PA; Lobzin, SV; Odinak, MM; Vozniuk, IA | 1 |
| Gershteĭn, LM; Sergutina, AV | 1 |
| Bobkova, NV; Bondarenko, NA; Gudasheva, TA; Ostrovskaya, RU; Retyunskaya, MV; Samokhin, AN | 1 |
| Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF | 1 |
| Chen, XH; Kui, Y; Li, Y | 1 |
| Lian, XF; Luo, XD | 1 |
| Chen, WJ; Lin, Y; Murong, SX; Wang, N; Wu, ZY; Xie, H; Zhao, GX | 1 |
| Ren, XM | 1 |
| Itoh, S; Oo, C | 1 |
| Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ | 1 |
| Castellanos, FX; Copland, DA; de Zubicaray, G; Di Martino, A; Kelly, C; Klein, DF; McMahon, K; Milham, MP; Reiss, PT | 1 |
| Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT | 1 |
| Hsu, CH; Wang, HB | 1 |
| Huang, Y; Jiang, X; Tang, A; Wik, G; Zhuo, Y | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 1 |
| Alvarez-Lueje, A; Bravo, M; Olivieri, AC; Pérez-Ortiz, M; Zapata-Urzúa, C | 1 |
| Kek, PC; Prakash, KM | 1 |
| Inoue, T; Koyama, M; Ogata, A; Tani, Y | 1 |
| Dick, OE; Nozdrachev, AD; Romanov, SP | 1 |
| Gershteĭn, LM; Rakhmanova, VI; Tatarintseva, IM | 1 |
| Assefi, AR; Bertuola, R; Czerniuk, P; Di Girolamo, G; Keller, GA; Spatz, JG | 1 |
| Egeland, M; Svenningsson, P; Zhang, X | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Asada, M; Asada, N; Fehling, HJ; Fukatsu, A; Kimura, T; Kita, T; Minegishi, N; Nagoshi, N; Nakamura, J; Oguchi, A; Okano, H; Rao, TN; Shibata, S; Suzuki, N; Takase, M; Yamamoto, M; Yamamura, K; Yanagita, M | 1 |
| Kuric, E; Ruscher, K; Wieloch, T | 1 |
| Bassetti, CL; Bornatico, F; Fuhr, P; Kallweit, U; Mathis, J; Schwander, J | 1 |
| Heekeren, K; Hitz, K; Huber, T; Juckel, G; Kawohl, W; Obermann, C | 1 |
| Bakheit, AM; Brennan, A; Fletcher, K | 1 |
| Li, M; Li, SD; Liu, Y; Yang, MH | 1 |
| Blau, N; Dill, P; Somerville, A; Thöny, B; Wagner, M; Weber, P | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Li, M; Liu, Y; Yang, MH | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Brasun, J; Kotynia, A; Malinka, W; Pap, JS; Szewczuk, Z; Szyrwiel, L | 1 |
| Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Arnet, I; Fischer, A; Gasser, UE; Timmermans, JP | 1 |
| Hodoba, D; Santic, AM; Schmidt, D | 1 |
| Ma, YZ; Shen, XM; Zhang, J | 1 |
| Almeida, KJ; Campos Sousa, RN; de Oliveira Filho, MC; Guimarães Silva, JS; Lopes Nery, PC | 1 |
| Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R | 1 |
| Kuric, E; Ruscher, K | 2 |
| Hattori, N | 1 |
| Deng, M; Fang, Y; Huang, L; Li, L; Zhang, S | 1 |
| Adrien, J; Arnulf, I; Belaid, H; Clark, SD; Drouot, X; François, C; Grabli, D; Hirsch, EC; Karachi, C; Laffrat, E; Tandé, D | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Alirezaei, M; Dezfoulian, O; Khoshdel, Z; Rashidipour, M; Taghadosi, V | 1 |
| Baumann, CR; Epprecht, L; Goetze, O; Schreglmann, SR; Waldvogel, D; Woitalla, D | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Cao, ZH; Chen, HX; Ding, ZG; Song, JH; Zhang, GB; Zhou, PY | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Chan, P; Feng, T; Hallett, M; Hou, Y; Wu, T; Zhang, J | 1 |
| Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P | 1 |
| Du, N; Guo, Z; Han, M; Huang, Y; Liu, J; Xu, S | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P | 1 |
| Cao, LD; Guo, G; Wu, QY; Xu, S | 1 |
| Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P | 1 |
| Bugdol, M; Czernek, M; Derejczyk, J; Kapko, W; Kawa, J; Marcisz, C; Seiffert, P; Stępień-Wyrobiec, O; Szymszal, J; Torbus, A | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
| Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z | 1 |
| Chang, MC; Lee, HD | 1 |
| Bloem, BR; Dirkx, MF; Hallett, M; Helmich, RC; Zach, H | 1 |
| Lim, SY; Ng, RX; Tan, AH | 1 |
| Hoppe, M; Koziolek, M; Schneider, F; Weitschies, W | 1 |
| Arnulfo, G; Canessa, A; Isaias, IU; Marotta, G; Olivieri, C; Palmisano, C; Pezzoli, G; Pozzi, NG; Turco, F; Volkmann, J | 1 |
| Ali, M; Chandel, TI; Jahan, I; Khan, RH; Masroor, A; Nayeem, SM; Siddique, IA; Uversky, VN; Zaidi, N; Zaman, M | 1 |
| Begemann, M; Damen, R; Elbracht, M; Häusler, M; Knopp, C; Kurth, I; Mull, M; Müller, B; Stoppe, A | 1 |
| Chen, L; Deng, F; Liu, X | 1 |
| Chen, Y; Lian, Y; Wang, C; Wang, R; Zhang, Y | 1 |
| Brandt, G; Canessa, A; Frigo, CA; Isaias, IU; Leporini, A; Maltese, V; Palmisano, C; Pezzoli, G; Pozzi, NG; Volkmann, J | 1 |
| Iggena, D; Klein, C; Rasińska, J; Sparenberg, M; Steiner, B; Winter, Y | 1 |
| Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L | 1 |
| Ding, YP; Lai, WL; Liu, HF; Qu, Y; Wang, L; Xin, YR; Xu, Y; Zhu, FQ; Zhu, Y | 1 |
| Carriere, J; Fukami, T; Hisada, H; Hoshino, T; Koide, T; Okayama, A; Yamamoto, Y | 1 |
| Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B | 1 |
| Cools, R; den Ouden, HEM; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, AJ; Zach, H | 1 |
| Biacchi, D; Cariddi, LP; Espay, AJ; Franciotta, D; Gastaldi, M; Mauri, M; Sturchio, A; Versino, M | 1 |
| Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ | 1 |
| Jiang, DQ; Jiang, LL; Li, MX; Qiao, JY; Wang, Y; Zang, QM | 1 |
| Castro, JC; Dalle, CR; Domingues-Hajj, PMS; Grandi-Miranda, FT; Milhomem, CBSS; Morais, BA; Reis, DM; Santos, UM; Silva, DJ; Souza, JT; Vilela-Filho, O | 1 |
| Che, NN; Chen, SY; Li, X; Ma, JJ; Yang, HQ | 1 |
| Al-Kaleel, A; Aygün, H; Erbaş, O | 1 |
7 review(s) available for ro 8-0576 and levodopa
| Article | Year |
|---|---|
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Picolinic Acids; Tolcapone | 1991 |
The hydrodynamically balanced system: a novel principle of controlled drug release.
Topics: Administration, Oral; Benserazide; Biological Availability; Capsules; Delayed-Action Preparations; Drug Combinations; Humans; Hydrazines; Levodopa | 1987 |
[Parkinson's disease and pregnancy: case report and literature review].
Topics: Adult; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Male; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2000 |
[Idiopathic Parkinson's disease: practical hints for the treatment].
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Benserazide; Cholinesterase Inhibitors; Clozapine; Dementia; Depression; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Quality of Life; Sleep Wake Disorders; Time Factors | 2005 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation | 2014 |
Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Topics: Acupuncture Therapy; Benserazide; Combined Modality Therapy; Dopamine Agents; Drug Combinations; Humans; Levodopa; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Pramipexole; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
59 trial(s) available for ro 8-0576 and levodopa
| Article | Year |
|---|---|
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Ergolines; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Parkinson Disease | 1992 |
A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Evaluation; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1991 |
Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Topics: Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine; Drug Combinations; Female; Follow-Up Studies; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Motor Skills; Multicenter Studies as Topic; Neurologic Examination; Parkinson Disease | 1990 |
Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Madopar HBS in nocturnal symptoms of Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Circadian Rhythm; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Sleep Stages | 1990 |
Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
Topics: Adult; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Is there a common dopaminergic basis of time perception and reaction time?
Topics: Adult; Benserazide; Brain; Clinical Trials as Topic; Dopamine Agents; Double-Blind Method; Drug Combinations; Haloperidol; Humans; Hydrazines; Levodopa; Male; Reaction Time; Receptors, Dopamine; Time Perception | 1989 |
A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
Topics: Activities of Daily Living; Aged; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 1989 |
A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Ergolines; Humans; Hydrazines; Infusion Pumps; Levodopa; Lisuride; Parkinson Disease; Severity of Illness Index | 1988 |
Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1988 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Biological Availability; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Infant, Newborn; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Hospitalization; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1987 |
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Disability Evaluation; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease; Random Allocation | 1987 |
[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Evaluation Studies as Topic; Gastrointestinal Diseases; Gymnastics; Humans; Hydrazines; Levodopa; Parkinson Disease; Speech Therapy | 1973 |
Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial.
Topics: Adolescent; Adult; Amantadine; Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Lipidoses; Psychoses, Substance-Induced; Syndrome | 1982 |
[Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease | 1994 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1993 |
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Motor Activity; Nitrophenols; Parkinson Disease; Placebos; Tolcapone | 1995 |
Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Denmark; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Norway; Parkinson Disease | 1996 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Movement; Parkinson Disease; Selegiline; Single-Blind Method | 1996 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
[The application of the pattern visual-evoked potential in the diagnosis and treatment of amblyopia].
Topics: Adolescent; Adult; Amblyopia; Benserazide; Child; Child, Preschool; Dopamine Agents; Drug Combinations; Evoked Potentials, Visual; Female; Humans; Levodopa; Male | 1995 |
[Efficiency of new forms of madopar in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2000 |
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Methyldopa; Reference Values | 2003 |
[Madopar in the complex therapy of ischemic insult].
Topics: Aged; Aged, 80 and over; Benserazide; Blood Pressure; Brain Ischemia; Cognition; Dopamine Agents; Drug Administration Schedule; Drug Combinations; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Stroke; Treatment Outcome | 2005 |
The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Topics: Adult; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Asian People; Benserazide; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Indoles; Levodopa; Linear Models; Male; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2007 |
[Clinical observation on abdominal acupuncture plus Madopa for treatment of Parkinson's disease].
Topics: Abdomen; Acupuncture Therapy; Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2007 |
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Medicine, Chinese Traditional; Middle Aged; Parkinson Disease; Phytotherapy; Prospective Studies; Syndrome; Treatment Outcome | 2007 |
Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Topics: Acupuncture Therapy; Aged; Benserazide; Combined Modality Therapy; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2008 |
L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study.
Topics: Adult; Benserazide; Brain Mapping; Cognition; Corpus Striatum; Dopamine Agents; Double-Blind Method; Drug Combinations; Female; Functional Laterality; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Movement; Neural Pathways; Neuropsychological Tests; Oxygen; Probability | 2009 |
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Topics: Administration, Oral; Adult; Area Under Curve; Azepines; Benserazide; China; Chromatography, Liquid; Cross-Over Studies; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Tablets; Tandem Mass Spectrometry | 2009 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Area Under Curve; Argentina; Benserazide; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drugs, Generic; Female; Humans; Levodopa; Male; Tablets; Therapeutic Equivalency; Young Adult | 2011 |
Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Topics: Adult; Aged; Benserazide; Benzothiazoles; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Pramipexole; Restless Legs Syndrome; Sleep; Treatment Outcome | 2011 |
Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans.
Topics: Administration, Oral; Adult; Benserazide; Dopamine Agents; Double-Blind Method; Drug Combinations; Evoked Potentials, Auditory; Female; Humans; Levodopa; Loudness Perception; Male; Young Adult | 2012 |
[Effects of bushenhuoxue granules on sleep quality in Parkinson's patients].
Topics: Aged; Aged, 80 and over; Benserazide; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2011 |
[Effects of "attenuation and synergia" for Bushenhuoxue Granules on Parkinson's patients].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Constipation; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phytotherapy; Plants, Medicinal; Treatment Outcome; Urination Disorders | 2012 |
Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Topics: Benserazide; Data Interpretation, Statistical; Drug Combinations; Drugs, Chinese Herbal; Humans; Levodopa; Medicine, Chinese Traditional; Parkinson Disease; Phytotherapy; Piribedil; Quality of Life | 2013 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2015 |
Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.
Topics: Adult; Aged; Appetite; Benserazide; Breath Tests; Caprylates; Dopamine Agents; Drug Combinations; Gastric Emptying; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies | 2015 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Periodicity; Piribedil; Postural Balance; Pramipexole; Walking | 2015 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Neural correlates underlying micrographia in Parkinson's disease.
Topics: Aged; Attention; Basal Ganglia; Benserazide; Brain Mapping; Case-Control Studies; Cerebellum; Drug Combinations; Female; Gyrus Cinguli; Handwriting; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Cortex; Neural Pathways; Parkinson Disease | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles; Parkinson Disease | 2016 |
Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Topics: Adult; Antiparkinson Agents; Benserazide; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxadiazoles | 2017 |
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Topics: Adult; Aged; Benserazide; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Combinations; Drugs, Generic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2019 |
134 other study(ies) available for ro 8-0576 and levodopa
| Article | Year |
|---|---|
[The effect of stimulation and blockade of the dopaminergic system on the choice of behavioral strategy by rats in the shuttle box].
Topics: Animals; Benserazide; Brain; Choice Behavior; Drug Combinations; Haloperidol; Levodopa; Male; Physical Stimulation; Rats; Reaction Time; Receptors, Dopamine; Stress, Psychological | 1992 |
Muscle stiffness and continuous electromyographic activity in old rats; an animal model for spasticity?
Topics: Aging; Animals; Atrophy; Baclofen; Benserazide; Drug Combinations; Electromyography; Female; Levodopa; Muscle Contraction; Muscle Denervation; Muscle Spasticity; Muscle Tonus; Muscles; Rats; Rats, Wistar | 1992 |
[Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamines; Animals; Apomorphine; Benserazide; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Parkinson Disease, Secondary | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Injections, Subcutaneous; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1992 |
Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Topics: Adult; Autonomic Nervous System Diseases; Benserazide; Delayed-Action Preparations; Drug Combinations; Fever; Humans; Levodopa; Male; Muscle Rigidity; Parkinson Disease | 1991 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; Levodopa; Long-Term Care; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Motor Skills; Neurologic Examination; Parkinson Disease | 1990 |
Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects.
Topics: Adult; Benserazide; Dopamine; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; Levodopa; Male; Stereoisomerism | 1990 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Parkinson Disease | 1989 |
Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
Topics: Aged; Aged, 80 and over; Benserazide; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; Levodopa; Male; Middle Aged; Parkinson Disease; Stereoisomerism | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levodopa; Locomotion; Male; Middle Aged; Parkinson Disease; Posture; Psychomotor Performance; Reaction Time | 1989 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Movement Disorders; Parkinson Disease | 1989 |
Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Topics: Aged; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carboxy-Lyases; Drug Combinations; Drug Therapy, Combination; Enzyme Induction; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1989 |
Pregnancy and parkinsonism. A case report without problem.
Topics: Adult; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; Pregnancy; Pregnancy Complications | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Phenytoin; Time Factors; Tyrosine | 1989 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease | 1989 |
Madopar HBS and the decompensated phase of Parkinson disease.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary | 1989 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Pain; Parkinson Disease; Time Factors | 1986 |
Optimization of symptomatic therapy in Parkinson's disease.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Computer-Assisted; Humans; Hydrazines; Levodopa; Models, Biological; Parkinson Disease; Reaction Time; Therapy, Computer-Assisted | 1989 |
Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
Topics: Adult; Aged; Benserazide; Dopamine; Drug Combinations; Female; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Insulin; Levodopa; Male; Middle Aged; Parkinson Disease; Pituitary-Adrenal System; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Pyridines; Selegiline | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodopa; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson Disease; Phenethylamines; Retrospective Studies; Selegiline; Time Factors | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; Phenethylamines; Selegiline | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Lisuride; Motor Skills; Parkinson Disease; Selegiline; Sleep Initiation and Maintenance Disorders | 1986 |
Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Topics: Administration, Oral; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Carbidopa; Delayed-Action Preparations; Dihydroxyphenylalanine; Dogs; Dopa Decarboxylase; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Kidney; Levodopa; Liver; Male; Mice; Rats; Time Factors; Tyrosine | 1987 |
L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Psychological Tests; Retrospective Studies | 1988 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1988 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Retrospective Studies | 1988 |
[Effect of L-dihydroxyphenylalanine on rat behavior and on catecholamine metabolism of the brain in rats with different degrees of emotional-behavioral reactivity].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Benserazide; Brain; Brain Chemistry; Catecholamines; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Emotions; Levodopa; Male; Rats | 1988 |
Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1987 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Topics: Adult; Antacids; Benserazide; Biological Availability; Delayed-Action Preparations; Drug Combinations; Eating; Gastric Mucosa; Humans; Hydrazines; Levodopa; Middle Aged; Stomach; Tyrosine | 1987 |
Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Topics: Administration, Oral; Adult; Benserazide; Biological Availability; Capsules; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hydrazines; Levodopa; Male; Middle Aged | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1987 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; Medical Audit; Parkinson Disease | 1986 |
Individual levodopa therapy in Parkinson's disease.
Topics: Benserazide; Chromatography, High Pressure Liquid; Drug Combinations; Gait; Humans; Levodopa; Parkinson Disease; Psychomotor Performance | 1987 |
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
Topics: Adult; Aged; Benserazide; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Life Expectancy; Longitudinal Studies; Male; Middle Aged; Models, Biological; Phenethylamines; Retrospective Studies; Selegiline | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Leg; Levodopa; Male; Middle Aged; Muscle Cramp; Parkinson Disease | 1985 |
Dopamine agonists in clinical research for new tardive dyskinesia treatments.
Topics: Adult; Aged; Antipsychotic Agents; Apomorphine; Benserazide; Carbidopa; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Hydrazines; Levodopa; Middle Aged; Synaptic Transmission | 1983 |
[Combined (surgical and drug) therapy of parkinsonism].
Topics: Benserazide; Catecholamines; Combined Modality Therapy; Diencephalon; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease; Stereotaxic Techniques | 1984 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1983 |
[Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Hydrazines; Levodopa; Middle Aged; Parkinson Disease, Secondary | 1984 |
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Topics: Aged; Benserazide; Drug Combinations; Electromyography; Female; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Phenylacetates; Thyrotropin; Thyrotropin-Releasing Hormone | 1980 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine; Triiodothyronine | 1982 |
A glimpse into Roche research: antiparkinson treatment.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Industry; History, 20th Century; Humans; Hydrazines; Levodopa; Male; Switzerland | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Rats | 1982 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Growth Hormone; Humans; Hydrazines; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Receptors, Dopamine | 1981 |
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Parkinson Disease | 1995 |
[Multilevel neurochemical organization of the brain].
Topics: Animals; Benserazide; Brain Chemistry; Carboxy-Lyases; Chinchilla; Drug Combinations; Levodopa; Neurochemistry; Rats; Rats, Wistar | 1994 |
Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Topics: Animals; Benserazide; Benzophenones; Biotransformation; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Enzyme Inhibitors; Half-Life; Injections, Intravenous; Levodopa; Male; Methylation; Nitrophenols; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Tissue Distribution; Tolcapone | 1995 |
[Pathochemical changes in the motor structures of the brain under the influence of the administration of L-DOPA preparations and their withdrawal (experimental research)].
Topics: Animals; Benserazide; Brain; Brain Chemistry; Drug Combinations; Histocytochemistry; Levodopa; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome; Time Factors | 1994 |
The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benserazide; Benzophenones; Catalepsy; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Synergism; Haloperidol; Kinetics; Levodopa; Male; Mice; Mice, Inbred C57BL; Nitrophenols; Tolcapone; Tyrosine | 1994 |
3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Topics: Animals; Benserazide; Catalepsy; Drug Combinations; Haloperidol; Levodopa; Male; Mice; Motor Activity; Tyrosine | 1994 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1995 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dyskinesia, Drug-Induced; Follow-Up Studies; Humans; Levodopa; Lisuride; Parkinson Disease; Reaction Time | 1994 |
[Madopar: more than 20 years].
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; History, 20th Century; Humans; Levodopa; Parkinson Disease | 1997 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Central pontine and extrapontine myelinolysis presenting with parkinsonism in a patient with cystic fibrosis.
Topics: Acute Disease; Adult; Antiparkinson Agents; Benserazide; Cystic Fibrosis; Drug Combinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Myelinolysis, Central Pontine; Parkinson Disease, Secondary; Pons | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Reaction Time; Receptors, Dopamine | 2000 |
[A case of delusional jealousy in Parkinson disease ].
Topics: Antiparkinson Agents; Benserazide; Delusions; Dose-Response Relationship, Drug; Drug Combinations; Humans; Jealousy; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 2001 |
A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping.
Topics: Alleles; Amino Acid Sequence; Aromatic Amino Acid Decarboxylase Inhibitors; Base Sequence; Benserazide; Biopterins; Cells, Cultured; Child, Preschool; Dihydroxyphenylalanine; Drug Combinations; Dystonia; Enzyme Inhibitors; Exons; Female; Fibroblasts; GTP Cyclohydrolase; Humans; Introns; Levodopa; Male; Mutation; Neopterin; RNA Splicing; RNA, Messenger | 2001 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug | 2002 |
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Dopamine; Drug Combinations; Drug Synergism; Drugs, Chinese Herbal; Homovanillic Acid; Levodopa; Male; Mice; Parkinson Disease, Secondary; Plant Extracts; Plants, Medicinal; Reserpine | 2002 |
A case report of dopa-responsive dystonia.
Topics: Adolescent; Antiparkinson Agents; Benserazide; Drug Combinations; Dystonia; Humans; Levodopa; Male | 2001 |
[Influence of L-DOPA on rat brain depending on individual behavioral features].
Topics: Animals; Behavior, Animal; Benserazide; Brain; Caudate Nucleus; Dopamine Agents; Drug Combinations; Hippocampus; Levodopa; Male; Motor Activity; Motor Cortex; Nucleus Accumbens; Rats; Rats, Inbred Strains; Rats, Wistar; Stress, Psychological; Time Factors | 2004 |
Cholinopositive effect of dilept (neurotensin peptidomimetic) as the basis of its mnemotropic effect.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Benserazide; Drug Combinations; Levodopa; Male; Memory; Mice; Mice, Inbred Strains; Muscarinic Antagonists; Neurotensin; Olfactory Bulb; Peptides; Rats; Rats, Wistar; Receptors, Muscarinic; Schizophrenia; Scopolamine; Space Perception | 2005 |
Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families.
Topics: Adolescent; Adult; Aged; Asian People; Benserazide; Child; Child, Preschool; Dopamine Agents; Drug Combinations; Dystonia; Female; Genetic Variation; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Mutation; Pedigree; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases; Young Adult | 2008 |
A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Drug Combinations; Feasibility Studies; Infusion Pumps; Intestinal Absorption; Intestinal Mucosa; Intestines; Levodopa; Male; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2010 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger | 2009 |
Severe gastroparesis in a patient with advanced Parkinson's disease.
Topics: Aged, 80 and over; Benserazide; Dopamine Agents; Drug Combinations; Enzyme Inhibitors; Follow-Up Studies; Gastroparesis; Humans; Levodopa; Male; Parkinson Disease; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Complementary acupuncture treatment increases cerebral metabolism in patients with Parkinson's disease.
Topics: Acupuncture Therapy; Aged; Antiparkinson Agents; Benserazide; Brain Chemistry; Combined Modality Therapy; Drug Combinations; Energy Metabolism; Female; Fluorodeoxyglucose F18; Glucose; Humans; Image Processing, Computer-Assisted; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals | 2009 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists | 2010 |
Simultaneous voltammetric determination of levodopa, carbidopa and benserazide in pharmaceuticals using multivariate calibration.
Topics: Algorithms; Benserazide; Calibration; Carbidopa; Dopamine Agents; Drug Combinations; Electrochemical Techniques; Electrodes; Excipients; Levodopa | 2010 |
Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
Topics: Antiparkinson Agents; Antithyroid Agents; Benserazide; Carbimazole; Drug Combinations; Female; Graves Disease; Heart Rate; Humans; Hyperthyroidism; Levodopa; Male; Middle Aged; Parkinson Disease; Thyroxine | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Partial Agonism; Dyskinesia, Drug-Induced; Hyperkinesis; Levodopa; Male; Microdialysis; Motor Activity; Oxazepines; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2010 |
Analysis of differences between physiological and pathological tremor of human fingers.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Electromyography; Fingers; Humans; Isometric Contraction; Levodopa; Middle Aged; Parkinson Disease; Tremor | 2010 |
[Morphological and chemical reorganizations in parietal cortical neurons in conditions of hyperactivity of the dopaminergic system].
Topics: Animals; Benserazide; Cell Nucleus; Cytoplasm; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Neurons; Parietal Lobe; Psychomotor Agitation; Rats; Rats, Wistar | 2010 |
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming | 2011 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.
Topics: Anemia; Animals; Benserazide; Cell Differentiation; Cell Lineage; Disease Models, Animal; Drug Combinations; Erythropoietin; Female; Fibroblasts; Fibrosis; Kidney; Levodopa; Mice; Mice, Transgenic; Myofibroblasts; Pregnancy | 2011 |
Levodopa treatment improves functional recovery after experimental stroke.
Topics: Animals; Antiparkinson Agents; Astrocytes; Benserazide; Blotting, Western; Cell Hypoxia; Cells, Cultured; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Combinations; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Glucose; Immunohistochemistry; Infarction, Middle Cerebral Artery; Levodopa; Male; Rats; Rats, Wistar; Receptors, Dopamine; Recovery of Function; Stroke | 2012 |
Successful treatment of severe abulia with co-beneldopa.
Topics: Benserazide; Cranial Fossa, Posterior; Dopamine Agents; Drug Combinations; Female; Humans; Hydrocephalus; Levodopa; Meningeal Neoplasms; Meningioma; Middle Aged; Psychomotor Disorders; Speech Disorders | 2011 |
Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency.
Topics: 5-Hydroxytryptophan; Alcohol Oxidoreductases; Behavior; Benserazide; Consanguinity; Developmental Disabilities; Dopamine Agents; Drug Combinations; Eye Movements; Female; Humans; Infant; Levodopa; Movement Disorders; Muscle Hypotonia; Nervous System Diseases; Neurotransmitter Agents; Phenylketonurias; Treatment Outcome | 2012 |
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution | 2012 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.
Topics: Antiparkinson Agents; Benserazide; Copper; Drug Combinations; Iron; Levodopa; Mass Spectrometry; Spectrophotometry, Ultraviolet; Zinc | 2013 |
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Injections, Intraventricular; Levodopa; Potassium; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Signal Transduction | 2013 |
Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
Topics: Benserazide; Capsules; Color; Dopamine Agents; Drug Combinations; Drugs, Generic; Humans; Levodopa; Parkinson Disease; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Quality Control; Tablets; Therapeutic Equivalency | 2013 |
Adjunctive Madopar for ultrarefractory epilepsy? Preliminary observations.
Topics: Adult; Anticonvulsants; Benserazide; Brain Injuries; Drug Combinations; Enzyme Inhibitors; Epilepsy; Follow-Up Studies; Humans; Intellectual Disability; Lennox Gastaut Syndrome; Levodopa; Male; Spasms, Infantile | 2013 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sexual Dysfunctions, Psychological | 2013 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease | 2014 |
Reversal of stroke induced lymphocytopenia by levodopa/benserazide treatment.
Topics: Animals; Benserazide; Drug Combinations; Levodopa; Lymphopenia; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Remission Induction; Single-Blind Method; Stroke; Treatment Outcome | 2014 |
Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Topics: 3,4-Dihydroxyphenylacetic Acid; Allylbenzene Derivatives; Animals; Anisoles; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopamine; Dopamine Agents; Drug Combinations; Drug Interactions; Homovanillic Acid; Levodopa; Male; Monoamine Oxidase; Rats; Serotonin; Tyrosine 3-Monooxygenase | 2014 |
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Muscle Tonus; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Polysomnography; Recombinant Fusion Proteins; Sleep Deprivation; Sleep Disorders, Intrinsic; Sleep, REM; Urotensins; Wakefulness | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain--influence of levodopa treatment.
Topics: Animals; Antigen-Presenting Cells; Benserazide; Brain; Cytokines; Disease Models, Animal; Dopamine Agents; Drug Combinations; Flow Cytometry; Functional Laterality; Histocompatibility Antigens Class II; Infarction, Middle Cerebral Artery; Levodopa; Macrophages; Male; Microglia; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.
Topics: Animals; Antioxidants; Benserazide; Betaine; Brain; Dopamine; Dopamine Agents; Drug Combinations; Glutathione; Glutathione Peroxidase; Humans; Hyperhomocysteinemia; Levodopa; Lipid Peroxidation; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Multiple System Atrophy; Parkinson Disease; Retrospective Studies | 2016 |
Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Hydrazines; Levodopa; Male; Mice, Inbred C57BL; Motor Activity; Neuroprotective Agents; Oxadiazoles; Oxidative Stress; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Parkinson Disease | 2016 |
Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Benserazide; Case-Control Studies; Cross-Sectional Studies; Dopamine; Dopamine Agents; Drug Combinations; Female; Frail Elderly; Frailty; Geriatric Assessment; Geriatrics; Humans; Inpatients; Levodopa; Male; Parkinson Disease; Phenotype; Poland; Predictive Value of Tests; Prevalence; Severity of Illness Index | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; Humans; Levodopa; Middle Aged; Motor Cortex; Muscle Rigidity; Muscular Atrophy, Spinal; Parkinson Disease; Positron-Emission Tomography; Tremor | 2017 |
The nature of postural tremor in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cluster Analysis; Dopamine; Drug Combinations; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Muscle, Skeletal; Parkinson Disease; Posture; Prevalence; Rest; Tremor | 2018 |
Osmotic Demyelination Syndrome With Evolving Movement Disorders.
Topics: Acute Disease; Adult; Akinetic Mutism; Athetosis; Benserazide; Chorea; Demyelinating Diseases; Dopamine Agents; Drug Combinations; Fluid Therapy; Gastroenteritis; Humans; Hyponatremia; Levodopa; Male; Myelinolysis, Central Pontine; Parkinsonian Disorders; Saline Solution; Time Factors | 2018 |
Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms.
Topics: Benserazide; Delayed-Action Preparations; Dosage Forms; Drug Combinations; Drug Delivery Systems; Drug Liberation; Enzyme Inhibitors; Fasting; Humans; Levodopa; Postprandial Period; Pressure; Stomach | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Drug-Induced; Electroencephalography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Parkinson Disease; Transcranial Magnetic Stimulation | 2018 |
A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin.
Topics: Amyloid; Benserazide; Cell Line, Tumor; Cell Survival; Dopamine Agents; Drug Combinations; Humans; Levodopa; Parkinson Disease; Protein Aggregates; Serum Albumin, Human | 2019 |
PDE10A mutation in two sisters with a hyperkinetic movement disorder - Response to levodopa.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Child; Consanguinity; Dopamine Agents; Drug Combinations; Epilepsy, Temporal Lobe; Exome Sequencing; Female; Humans; Hyperkinesis; Infant; Levodopa; Movement Disorders; Phosphoric Diester Hydrolases; Siblings | 2019 |
Parkinsonism Caused by Viral Encephalitis Affecting the Bilateral Substantia Nigra.
Topics: Acyclovir; Benserazide; Drug Combinations; Drug Therapy, Combination; Encephalitis, Viral; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra; Young Adult | 2019 |
Hypnic Headache with Dopaminergic Neuron Dysfunction: New Insight from a Rare Case.
Topics: Benserazide; Brain; Cocaine; Dopamine Agents; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Drug Combinations; Fluorodeoxyglucose F18; Headache Disorders, Primary; Humans; Levodopa; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Putamen; Radiopharmaceuticals | 2019 |
Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benserazide; Case-Control Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Postural Balance; Quality of Life; Sensitivity and Specificity; Sitting Position; Walking | 2019 |
Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Female; Green Fluorescent Proteins; Hippocampus; Levodopa; Maze Learning; Memory; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; MPTP Poisoning; Neurogenesis; Random Allocation; Sedentary Behavior | 2019 |
Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Capsules; Cation Exchange Resins; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Levodopa; Lipids; Male; Rats; Suspensions; Tablets, Enteric-Coated | 2019 |
Determining the Distribution of Active Pharmaceutical Ingredients in Combination Tablets Using Near IR and Low-Frequency Raman Spectroscopy Imaging.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Levodopa; Spectroscopy, Near-Infrared; Spectrum Analysis, Raman; Tablets | 2020 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sepsis; Sepsis-Associated Encephalopathy | 2020 |
Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
Topics: Aged; Antiparkinson Agents; Benserazide; Computer Simulation; Conditioning, Operant; Dopamine Agonists; Drug Combinations; Female; Humans; Learning; Levodopa; Male; Middle Aged; Motivation; Parkinson Disease; Phenotype; Punishment; Reward; Tremor | 2020 |
Levodopa-responsive progressive encephalomyelitis with rigidity and myoclonus associated with glycine receptor antibodies.
Topics: Adult; Autoantibodies; Autoimmune Diseases of the Nervous System; Benserazide; Dopamine Agents; Drug Combinations; Encephalomyelitis; Humans; Levodopa; Male; Muscle Rigidity; Myoclonus; Receptors, Glycine | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Microscopic; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies | 2021 |
Induction of Ticlike Involuntary Movements in Rats by Striatotomy and Subsequent Neurochemical Sensitization.
Topics: Analgesics, Non-Narcotic; Animals; Benserazide; Corpus Striatum; Dopamine Agents; Double-Blind Method; Drug Combinations; Ergotamine; Female; Globus Pallidus; Levodopa; Naloxone; Prospective Studies; Rats; Rats, Wistar; Stereotaxic Techniques; Tourette Syndrome | 2021 |
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benserazide; Cognitive Dysfunction; Drug Combinations; Fever of Unknown Origin; Handwriting; Humans; Immunosuppressive Agents; Immunotherapy; Levodopa; Male; Methylprednisolone; Neuropsychological Tests; Parkinson Disease, Secondary; Tremor | 2021 |
The effect of Madopar on absence‑like seizures in WAG/Rij rats.
Topics: Animals; Benserazide; Disease Models, Animal; Drug Combinations; Electroencephalography; Epilepsy, Absence; Levodopa; Male; Rats; Rats, Wistar; Seizures | 2022 |